---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-018677"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:30:03.567853+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics authorizes $10M stock repurchase program through Dec 31, 2023

## Summary
- Board approved repurchase of up to $10M of common stock through December 31, 2023.
- Program is less than 10% of total cash as of March 31, 2023; cash runway exceeds three years.
- Repurchases may occur in open market or private transactions; no obligation to buy any shares.
- CEO states confidence in strategic priorities; CFO cites attractive valuation opportunity.
- Program may be suspended, modified, or terminated at any time without prior notice.

## SEC filing metadata
- accession: 0001437749-23-018677
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923018677/0001437749-23-018677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923018677/atos20230627_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-018677
- JSON: https://secwatch.observer/filing/0001437749-23-018677.json
- Plain text: https://secwatch.observer/filing/0001437749-23-018677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.